PENSACOLA, Fla., Feb. 4, 2026 /PRNewswire/ -- Regenative Labs, in collaboration with Babak Baravarian, DPM, Director of Foot & Ankle Research at University Foot & Ankle Institute, today announced the publication of a new observational case series examining the use of Wharton's jelly connective tissue allografts in patients with plantar fascia defects associated to plantar fasciopathy. Continue Reading Clinical examination image showing manual palpation of the medial plantar heel at the calcaneal

An opportunity to reduce global burden of stroke-related disability SAN ANTONIO, Feb. 4, 2026 /PRNewswire/ -- For many stroke survivors, recovery is derailed by painful muscle stiffness and involuntary spasms that limit movement, independence and quality of life. Often viewed as an unavoidable consequence of stroke, this condition – known as post-stroke spasticity – may instead represent a missed opportunity for earlier, more effective care. Two researchers at UT Health San Antonio led the writi

Arovella Therapeutics is pleased to provide an update to investors in the form of the below presentation. The presentation will be used in Arovella’s non-deal investor meetings in Perth, Sydney and Melbourne from 5th-10th of February. View presentation

Becoming a clinical-stage company Dear Arovella Shareholders, Colleagues and Friends, We are well into 2026 and believe it is an ideal time to pause, reflect, and explain the significance of the Investigational New Drug (IND) application acceptance for ALA-101 by the U.S. Food and Drug Administration (FDA). The acceptance of the IND marks a pivotal milestone for the Company and validates Arovella’s preclinical data and clinical development plan. Most importantly, it also confirms the extensive w

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutics, Binhui Biopharmaceutical, Oncolytics Biotech, EpicentRx, Hangzhou Converd, and others, anchor the mid and late-stage pipeline. LAS VEGAS, Feb. 4, 2026 /PRNewswire/ -- DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic viru

Bipartisan support advances life-saving discovery for patients nationwide MILWAUKEE, Feb. 4, 2026 /PRNewswire/ -- The federal government funding bill, signed into law on Feb. 3, includes $3 million in support of the Versiti Blood Research Institute (VBRI) expansion in Wauwatosa, Wis. The bipartisan investment will help fund a new facility addition that accelerates groundbreaking research into cancer, bleeding disorders, clotting conditions, and cellular therapies. This federal support builds on

We’ve built a straightforward way to access a practical and effective alternative to suffering in silence.” — Karen Brunet, founder of Cntrl+ OTTAWA, ONTARIO, CANADA, February 4, 2026 / EINPresswire.com / -- Cntrl+ , an Ontario–based women’s health company, today announced the launch of its FDA-cleared, reusable vaginal support product designed to reduce symptoms of stress urinary incontinence (SUI) and help women move with greater confidence and control. Cntrl+ is a prescription intravaginal pr

MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR® Extended-Relea

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. The affected products have not changed, but the “Full list of affected lots” has been modified for clarity. The recommendations for what to do with the devices below have not changed. The reason for recall has been clarified and updated with current information. Affected Product The FD

High‑specialty oncology pharmacy strengthens cold‑chain logistics, technical support, and medical education for responsible use of anti‑CD20 therapies. Now more than ever, high‑impact biological therapies must be supported by specialized counselling and robust logistics processes.” — Official spokesperson for OncoEspecializados MEXICO CITY, MEXICO, MEXICO, February 4, 2026 / EINPresswire.com / -- OncoEspecializados , a high‑specialty oncology pharmacy with nationwide coverage, announces a compre